Grifols to take full ownership of Alkahest in $146m deal

Alkahest is a clinical stage company that is focussed on the discovery and development of treatments for neurodegenerative and age-related diseases with therapies that target the aging plasma proteome.

The drug candidates cover therapeutic products for neurodegenerative, cognitive decline, neuromuscular and ophthalmic indications.

Grifols co-CEO Víctor Grífols said: “We saw the promise of Alkahest’s understanding of aging when we made our first investment and entered into a collaboration agreement with them five years ago.

The US firm, as a fully-owned subsidiary within the Grifols innovation office (GIANT), will work on proteins with biological effects that change with age.

So far, over 8,000 separate proteins are said to have been identified by Alkahest and through advanced techniques of molecular analysis at the cellular level.

Grifols said that the deal will help in adding a range of new products to its discovery and development pipeline, which will help roll out new therapeutic medicines to market.

Powered by Blogger.